About 4E Therapeutics
4E Therapeutics is a Healthcare company based in Austin (United States) founded in 2019 by Joe Price and Craig Benson, and was acquired by Lilly in June 2026. Non-opioid drugs for neuropathic pain are developed through novel mechanisms. It operates on a HealthTech model. 4E Therapeutics has raised $1.89 million across 1 funding round from investors including Lilly. Its chief executive, as recorded, is Craig Benson. 4E Therapeutics offers products and services including Neuropathic Pain Treatment, Migraine Treatment, and Acute Pain Treatment. Its focus areas include Biotechnology and Neuroscience. Its legal entity is 4E Therapeutics Inc. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
4E Therapeutics is focused on developing next-generation treatments for neuropathic pain. Based in Austin, Texas, the company targets underlying neurological mechanisms causing pain. Solutions are created for chronic neuropathic pain, migraine, and acute pain. The neuroscience sector is prioritized with a commitment to non-addictive medications. Clinical development has been initiated for cutting-edge therapies. Research and innovation are driven by a world-class team of experts.
- Headquarters Austin, United States
- Founders Joe Price, Craig Benson
- Stage Acquired
- SectorsHealthcare
- Website 4etherapeutics.com
- Social LinkedIn X
- Acquired by Lilly (Jun 2026)
- Legal Name 4E Therapeutics Inc
Products & Services of 4E Therapeutics
4E Therapeutics offers a comprehensive portfolio of products and services, including Neuropathic Pain Treatment, Migraine Treatment, and Acute Pain Treatment.
Innovative therapy developed for chronic neuropathic pain relief.
Compounds being researched for effective migraine pain management.
Solutions under development for managing acute pain conditions.
Funding Insights of 4E Therapeutics
4E Therapeutics has successfully raised a total of $1.89M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.89 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.89M
- Total Rounds 1
- Last Round Seed — $1.89M
- First Round $1.89M
(Nov 2021)
All 1 funding rounds of 4E Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $1.89M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in 4E Therapeutics
4E Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Lilly.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for 4E Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of 4E Therapeutics
2 people are tracked at 4E Therapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Joe Price | Co-Founder & President | Leadership |
Craig Benson | Co-Founder & CEO | Leadership |
Complete people profiles for 4E Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of 4E Therapeutics
3 dated milestones of 4E Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded 4E Therapeutics is founded.
- Funding First funding round of $1.9M.
- Exit Acquired by Lilly.
Competitors of 4E Therapeutics
4E Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. |
Detailed competitors of 4E Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of 4E Therapeutics
The website of 4E Therapeutics (4etherapeutics.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 32.3% vs previous month
Top companies in Pain Management
3 companies that operate in the same segment as 4E Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 4E Therapeutics
4E Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
4E Therapeutics is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Craig Benson is the CEO of 4E Therapeutics, as recorded in our data. They have also founded this company.
4E Therapeutics is a funded company, having raised a total of $1.89M across 1 funding round to date. The company's 1st funding round was a Seed of $1.89M, raised on Nov 2021.
4E Therapeutics is focused on developing next-generation treatments for neuropathic pain. Based in Austin, Texas, the company targets underlying neurological mechanisms causing pain. Solutions are created for chronic neuropathic pain, migraine, and acute pain. The neuroscience sector is prioritized with a commitment to non-addictive medications. Clinical development has been initiated for cutting-edge therapies. Research and innovation are driven by a world-class team of experts.
4E Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
4E Therapeutics offers Neuropathic Pain Treatment, Migraine Treatment, and Acute Pain Treatment.
4E Therapeutics has 1 investor. Key investors include Lilly.
4E Therapeutics operates through 4E Therapeutics Inc.
Yes. 4E Therapeutics was acquired by Lilly in June 2026.